Literature DB >> 34325427

Use of the Montreal Cognitive Assessment Thai Version to Discriminate Amnestic Mild Cognitive Impairment from Alzheimer's Disease and Healthy Controls: Machine Learning Results.

Solaphat Hemrungrojn1,2, Sookjaroen Tangwongchai3, Thammanard Charoenboon4, Muthita Panasawat5, Thitiporn Supasitthumrong3, Pisit Chaipresertsud6, Pacharaporn Maleevach7, Yuttachai Likitjaroen8, Kammant Phanthumchinda8, Michael Maes3,9,10.   

Abstract

BACKGROUND: The Montreal Cognitive Assessment (MoCA) is an effective and applicable screening instrument to confirm the diagnosis of amnestic mild cognitive impairment (aMCI) from patients with Alzheimer's disease (AD) and healthy controls (HCs).
OBJECTIVES: This study aimed to determine the reliability and validity of the following: (a) Thai translation of the MoCA (MoCA-Thai) and (b) delineate the key features of aMCI based on the MoCA subdomains.
METHODS: This study included 60 HCs, 61 aMCI patients, and 60 AD patients. The MoCA-Thai shows adequate psychometric properties including internal consistency, concurrent validity, test-retest validity, and inter-rater reliability.
RESULTS: The MoCA-Thai may be employed as a diagnostic criterion to make the diagnosis of aMCI, whereby aMCI patients are discriminated from HC with an area under the receiver-operating characteristic (AUC-ROC) curve of 0.813 and from AD patients with an AUC-ROC curve of 0.938. The best cutoff scores of the MoCA-Thai to discriminate aMCI from HC is ≤24 and from AD > 16. Neural network analysis showed that (a) aberrations in recall was the most important feature of aMCI versus HC with impairments in language and orientation being the second and third most important features and (b) aberrations in visuospatial skills and executive functions were the most important features of AD versus aMCI and that impairments in recall, language, and orientation but not attention, concentration, and working memory, further discriminated AD from aMCI.
CONCLUSIONS: The MoCA-Thai is an appropriate cognitive assessment tool to be used in the Thai population for the diagnosis of aMCI and AD.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Alzheimer’s disease; Diagnosis; Mild cognitive impairment; Montreal Cognitive Assessment

Mesh:

Year:  2021        PMID: 34325427     DOI: 10.1159/000517822

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  4 in total

1.  Gait variability during abrupt slow and fast speed transitions in older adults with mild cognitive impairment.

Authors:  Sirinun Boripuntakul; Teerawat Kamnardsiri; Stephen Ronald Lord; Surinthorn Maiarin; Puangsoi Worakul; Somporn Sungkarat
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Efficacy and Safety of Kleeb Bua Daeng Formula in Mild Cognitive Impairment Patients: A Phase I Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Natdanai Musigavong; Chantana Boonyarat; Yaowared Chulikhit; Orawan Monthakantirat; Makorn Limudomporn; Supaporn Pitiporn; Pakakrong Kwankhao; Supawadee Daodee
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

3.  Selecting the Most Important Features for Predicting Mild Cognitive Impairment from Thai Verbal Fluency Assessments.

Authors:  Suppat Metarugcheep; Proadpran Punyabukkana; Dittaya Wanvarie; Solaphat Hemrungrojn; Chaipat Chunharas; Ploy N Pratanwanich
Journal:  Sensors (Basel)       Date:  2022-08-03       Impact factor: 3.847

4.  Neurocognitive performance and quality of life of older adults with HIV on antiretroviral treatment in Northern Thailand.

Authors:  Linda Aurpibul; Patumrat Sripan; Arunrat Tangmunkongvorakul; Wilawan Chaikan; Saowalak Sarachai; Kriengkrai Srithanaviboonchai
Journal:  J Int AIDS Soc       Date:  2022-09       Impact factor: 6.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.